Delaying the inevitable?

A commonly expressed concern about building new antibiotics on the scaffolds of failing first-generation compounds is that the new drugs typically target the same molecular pathways as the originals and therefore microbes resistant to the old compound will rapidly become resistant to the new ones.
| 1 min read
Register for free to listen to this article
Listen with Speechify
0:00
1:00
A commonly expressed concern about building new antibiotics on the scaffolds of failing first-generation compounds is that the new drugs typically target the same molecular pathways as the originals and therefore microbes resistant to the old compound will rapidly become resistant to the new ones. Dr. Jon Thorson, a pharmaceutical scientist at University of Wisconsin-Madison, sees it differently (see also Decorating old drugs to combat resistance).
 
"Antibiotics target elements unique to the life of the pathogenic bacteria and regardless of whether the antibiotic hits a newly discovered or more classical antibiotic target, microbes counter by mutating the antibiotic target to prohibit the antibiotic from binding or by picking up genes that encode for enzymes to inactivate the antibiotic via chemical modification or pump the antibiotic out of the cell," he says. "A next-generation antibiotic must then be able to bind the mutated target and/or not be recognized by the antibiotic-inactivating machinery.
 
"To stay ahead in this constant struggle, innovative strategies to rapidly generate and screen variants of 'new' or old antibiotics are needed," he continues. "Moreover, as exemplified by the lipoglycopeptides, structural modifications of existing antibiotic scaffolds can actually redirect the drug to a new biological target."
 
Besides, he says, "Given the rapid growth rate of microbes and their ability adapt under selective pressure, microbial drug resistance will remain a constant threat."
 

About the Author

Related Topics

Published In

Loading Next Article...
Loading Next Article...
Subscribe to Newsletter

Subscribe to our eNewsletters

Stay connected with all of the latest from Drug Discovery News.

Subscribe

Sponsored

Tackling mycoplasma contamination in biotherapeutic production
DNA-based testing is emerging as a sensitive way to uncover and control a hidden threat in biomanufacturing.
Surface rendering of two interacting proteins (green and peach) bound together by a small molecule ligand at their interface, illustrating a protein-ligand binding event.
Learn how molecular dynamics, AI-aided design, and structural insights combine to reshape how therapeutic proteins are created, validated, and optimized.
Stem cells are shown as clear, purple, and blue spheres against a dark blue and black background.
Human-relevant, ready-to-use stem cell models are reshaping drug discovery, toxicity testing, and personalized medicine.
Drug Discovery News June 2025 Issue
Latest IssueVolume 21 • Issue 2 • June 2025

June 2025

June 2025 Issue

Explore this issue